Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2493 - Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immunotherapy for metastatic renal cell carcinoma (mRCC)

Date

10 Sep 2017

Session

Poster display session

Topics

Immunotherapy;  Renal Cell Cancer

Presenters

Aly-Khan Lalani

Citation

Annals of Oncology (2017) 28 (suppl_5): v295-v329. 10.1093/annonc/mdx371

Authors

A.A. Lalani1, W. Xie2, D.J. Martini1, C.K. Norton1, J.A. Steinharter1, D. Bossé1, J. Bellmunt1, E.M. Van Allen1, B.A. McGregor1, L.C. Harshman1, T.K. Choueiri1

Author affiliations

  • 1 Lank Center For Genitourinary Oncology, Dana-Farber Cancer Institute, 02215 - Boston/US
  • 2 Dept. Of Biostatistics And Computational Biology, Dana-Farber Cancer Institute, 02215 - Boston/US
More

Resources

Abstract 2493

Background

Elevated NLR is associated with worse outcomes in several malignancies, including mRCC. However, its role in the current immunotherapy era is unknown. We investigated the utility of NLR at baseline and during therapy in mRCC patients treated with PD-1/PD-L1 immunotherapy (IO).

Methods

116 patients from Dana-Farber Cancer Institute (Boston, MA) receiving IO-based therapies were included. NLR was examined at baseline and 6 (±2) weeks later. Landmark analysis at 6 weeks was conducted to explore the prognostic value of relative NLR change on overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) using Cox or logistic regression models, adjusted for line of therapy, number of IMDC risk factors, histology and baseline NLR.

Results

Median follow up was 16.3 months (range: 1.4-64.2). Median duration on therapy was 7 months (

Conclusions

Early decline and NLR at 6-weeks are associated with significantly improved outcomes in mRCC patients treated with IO, whereas an increase is associated with worse outcomes. The prognostic value of the readily-available NLR warrants larger, prospective validation.Table:

888P

ORR(CR+PR)PFSOS
NAdjusted-ORp-valueAdjusted-HRp-valueAdjusted-HRp-value
Continuous Ln(NLR) Baseline**1160.58 (0.23-1.42)0.2321.36 (0.78-2.37)0.2691.74 (0.82-3.69)0.147
Continuous Ln(NLR) 6-weeks**1130.28 (0.11-0.69)0.0062.39 (1.38-4.15)0.0023.24 (1.83-5.74)

Clinical trial identification

N/A

Legal entity responsible for the study

Dana-Farber/Harvard Cancer Center

Funding

None

Disclosure

J. Bellmunt: Research support from Novartis and Sanofi; consulting support from OncoGenex, AstraZeneca, Merck, Bristol Myers-Squibb, Genentech, Inovio, Champions Oncology, Seattle Genetics and Pierre Fabre. E.M. Van Allen: Stock and Other Ownership Interests: Syapse; Consulting or Advisory Role: Novartis, Roche, Syapse, Takeda, Third Rock Ventures; Research Funding: Bristol-Myers Squibb T.K. Choueiri: Consulting: Bayer, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Novartis, Pfizer; Research Funding: AstraZeneca, Bristol-Myers Squibb, Exelixis, GlaxoSmithKline, Merck, Novartis, Peloton Therapeutics, Pfizer, Roche/Genentech, TRACON Pharma. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.